|
1.
|
|
8 p, 732.8 KB |
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation
/
Gagelmann, N. (University Medical Center Hamburg-Eppendorf) ;
Eikema, D.J. (EBMT Statistics) ;
Stelljes, M. (University of Münster) ;
Beelen, D. (Department of Bone Marrow Transplantation. West German Cancer Center. University Hospital of Essen) ;
de Wreede, L. (EBMT Statistics) ;
Mufti, G. (GKT School of Medicine) ;
Knelange, N.S. (EBMT Data Office) ;
Niederwieser, D. (University Hospital Leipzig) ;
Friis, L.S. (Rigshospitalet) ;
Ehninger, G. (Universitätsklinikum Dresden) ;
Nagler, A. (Chaim Sheba Medical Center) ;
Yakoub-Agha, I. (CHU de Lille. LIRIC. INSERM U995. Université Lille2) ;
Meijer, E. (VU University Medical Center) ;
Ljungman, P. (Karolinska University Hospital and Karolinska Institutet) ;
Maertens, J. (University Hospital Gasthuisberg) ;
Kanz, L. (Universität Tübingen) ;
Lopez-Corral, L. (Hospital Clínico) ;
Brecht, A. (Deutsche Klinik für Diagnostik) ;
Craddock, C. (Centre for Clinical Haematology) ;
Finke, J. (University of Freiburg) ;
Cornelissen, J.J. (Erasmus MC Cancer Institute. Erasmus University Medical Center) ;
Bernasconi, P. (Fondazione IRCCS Policlinico San Matteo) ;
Chevallier, P. (CHU Nantes) ;
Sierra, Jorge (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Robin, M. (Hopital St. Louis) ;
Kröger, N. (University Medical Center Hamburg-Eppendorf) ;
Universitat Autònoma de Barcelona
The aim of this study was to develop and validate a clinical and transplant-specific prognostic score using data from a large cohort of patients with myelodysplastic syndromes reported to the European Society for Blood and Marrow Transplantation registry. [...]
2019 -  10.3324/haematol.2018.200808
Haematologica, Vol. 104 Núm. 5 (30 2019) , p. 929-936
|
|
|
2.
|
|
13 p, 1.0 MB |
Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia : A comparative study of the ALWP EBMT
/
Sanz, Jaime (CIBERONC. Instituto Carlos III) ;
Galimard, J.E. (EBMT Paris Office. Hospital Saint Antoine) ;
Labopin, M. (Department of Hematology. Hopital Saint Antoine. Sorbonne University) ;
Afanasyev, B. (First State Pavlov Medical University of St. Petersburg. Raisa Gorbacheva Mem. Research Institute for Paediatric Oncology. Hematology. and Transplantation) ;
Angelucci, E. (Department of Haematology. IRCCS Ospedale Policlinico San Martino) ;
Ciceri, F. (Haematology and BMT) ;
Blaise, D. (Programme de Transplantation and Therapie Cellulaire. Centre de Recherche en Cancérologie de Marseille. Institut Paoli Calmettes) ;
Cornelissen, J.J. (Department of Hematology. Erasmus MC Cancer Institute. University Medical Center Rotterdam) ;
Meijer, E. (Department of Hematology (Br 250). VU University Medical Center) ;
Diez-Martin, J.L. (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
Koc, Y. (Stem Cell Transplant Unit. Medical Park Hospitals) ;
Rovira Tarrats, Montserrat (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Castagna, L. (Transplantation Unit. Department of Oncology and Haematology. Istituto Clinico Humanitas) ;
Savani, B. (Vanderbilt University Medical Center) ;
Ruggeri, A. (Department of Pediatric Hematology and Oncology. IRCCS Bambino Gesù Children's Hospital) ;
Nagler, A. (ALWP of the EBMT Office. Saint Antoine Hospital) ;
Mohty, M. (Department of Hematology. Hopital Saint Antoine. Sorbonne University) ;
Universitat Autònoma de Barcelona
Background: The use of post-transplant cyclophosphamide (PTCy) is highly effective in preventing graft-versus-host disease (GVHD) in the haploidentical (Haplo) transplant setting and is being increasingly used in matched sibling (MSD) and matched unrelated (MUD) transplants. [...]
2020 - 10.1186/s13045-020-00882-6
Journal of hematology & oncology, Vol. 13 Núm. 1 (june 2020) , p. 46
|
|
|
3.
|
|
11 p, 572.5 KB |
Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients : a position statement from an international expert group
/
Mohty, M. (Hematology Department. AP-HP. Hôpital Saint-Antoine. Sorbonne Université) ;
Malard, F. (Hematology Department. AP-HP. Hôpital Saint-Antoine. Sorbonne Université) ;
Abecasis, M. (Instituto Portugues de Oncologia) ;
Aerts, E. (Department of Internal Medicine-Oncology. University Hospital Zurich) ;
Alaskar, A.S. (Department of Oncology. King Abdulaziz Medical City. King Abdullah International Medical Research Center. King Saud Bin Abdulaziz University for Health Sciences. Ministry of National Guard Health Affairs) ;
Aljurf, M. (King Faisal Specialist Hospital and Research Centre) ;
Arat, M. (HSCT Unit. Sisli Florence Nightingale Hospital) ;
Bader, P. (Division for Stem Cell Transplantation and Immunology. Department for Children and Adolescents. University Hospital. Goethe University) ;
Baron, F. (Department of Hematology. University of Liege) ;
Basak, G. (Medical University of Warsaw) ;
Bazarbachi, A. (Department of Internal Medicine. American University of Beirut) ;
Blaise, D. (Transplant and Cellular Immunotherapy Program. Department of Hematology. Aix-Marseille Univ. Inserm. CNRS. Institut Paoli-Calmettes. CRCM) ;
Ciceri, F. (Hematology and Bone Marrow Transplantation Unit. IRCCS Ospedale San Raffaele. University Vita-Salute) ;
Corbacioglu, S. (Department of Pediatric Hematology. Oncology and Stem Cell Transplantation. University of Regensburg) ;
Dalle, J.H. (Department of Hematology and Immunology. Hospital Robert Debre. Paris 7-Paris Diderot University) ;
Dignan, F. (Department of Clinical Haematology. Central Manchester Foundation Trust) ;
Fukuda, T. (HSCT Division. National Cancer Center Hospital) ;
Huynh, A. (Hematology Department. Institut Universitaire du Cancer Toulouse-Oncopole) ;
Kuball, J. (Department of Haematology. University Medical Centre) ;
Lachance, S. (Department of Hematology and Stem Cell Transplant Program. Hôpital Maisonneuve-Rosemont. University of Montreal) ;
Lazarus, H. (Case Western Reserve University) ;
Masszi, T. (Department of Hematology and Stem Cell Transplantation. St. Istvan and St. Laszlo Hospital. Budapest 3 Department of Internal Medicine. Semmelweis University) ;
Michallet, M. (Hematology Department. Groupement Hospitalier Sud. Hospices Civils de Lyon. Université Claude Bernard Lyon EST) ;
Nagler, A. (Hematology and Bone Marrow Transplantation. Chaim Sheba Medical Center) ;
NiChonghaile, M. (National Stem Cell Transplant Unit (Adults). Department of Haematology. St James's Hospital and Academic Department of Haematology. Trinity College Dublin) ;
Okamoto, S. (Division of Hematology. Department of Medicine. Keio University School of Medicine) ;
Pagliuca, A. (Department of Haematological Medicine. King's College Hospital) ;
Peters, C. (Department of Pediatrics. St. Anna Kinderspital) ;
Petersen, F.B. (LDS Hospital) ;
Richardson, P.G. (Division of Hematology. Mayo Clinic) ;
Ruutu, T. (Clinical Research Institute. Helsinki University Hospital) ;
Saber, W. (Center for International Blood and Marrow Transplant Research. Medical College of Wisconsin) ;
Savani, B.N. (Hematology and Stem Cell Transplantation Section. Division of Hematology/Oncology. Department of Medicine. Vanderbilt University Medical Center and Veterans Affairs Medical Center) ;
Soiffer, R. (Division of Hematologic Malignancies. Dana-Farber Cancer Institute) ;
Styczynski, J. (Pediatric Hematology and Oncology. University Hospital. Collegium Medicum UMK) ;
Wallhult, E. (Section of Haematology and Coagulation. Department of Internal Medicine. Sahlgrenska University Hospital) ;
Yakoub-Agha, I. (CHU de Lille. LIRIC INSERM U995. Université de Lille2) ;
Duarte, R.F. (Department of Hematology. Hospital Universitario Puerta de Hierro Majadahonda) ;
Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
2020 - 10.1038/s41409-019-0705-z
Bone marrow transplantation, Vol. 55 Núm. 3 (january 2020) , p. 485-495
|
|
|
4.
|
|
8 p, 788.7 KB |
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
/
Hájek, R. (University Hospital Ostrava) ;
Masszi, T (St István and St László Hospital of Budapest) ;
Petrucci,M.T. (Sapienza Università di Roma) ;
Palumbo, A. (Università di Torino) ;
Rosiñol, L. (Hospital Clínic de Barcelona) ;
Nagler, Arnon. (Chaim Sheba Medical Center (Israel)) ;
Yong, K.L. (University College London Cancer Institute) ;
Oriol, A. (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ;
Minarik, J. (University Hospital Olomouc and Medical Faculty of Palacky) ;
Pour, L (University Hospital Ostrava) ;
Dimopoulos, M.A. (National and Kapodistrian University of Athens) ;
Maisnar, V. (Charles University Teaching Hospital, Hradec Králové) ;
Rossi, D. (Amedeo Avogadro University of Eastern Piedmont) ;
Kasparu, H. (Hospital Elisabethinen Linz) ;
Van Droogenbroeck, J. (AZ Sint-Jan, Brugge, Belgium) ;
Yehuda, D.B. (Hadassah Medical Center, Jerusalem, Israel) ;
Hardan, I. (Meir Medical Center, Kfar-Saba, Israel) ;
Jenner, M. (Southampton General Hospital, Hampshire, UK) ;
Calbecka, M. (Nicolaus Copernicus Hospital, Toruń Poland) ;
Dávid, M. (University of Pécs, Hungary) ;
de la Rubia, J. (Hospital Universitario La Fe, València) ;
Drach, J. (Medical University of Vienna) ;
Gasztonyi, Z. (Petz Aladár Megyei Oktató Kórház, Vasvári Pál, Hungary) ;
Górnik, S. (Zamojski Szpital Niepubliczny, Zamosc, Poland) ;
Leleu, X. (Hopital Huriez, CHRU, Lille, France) ;
Munder, M. (University Medicine Mainz, Germany) ;
Offidani, M (Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Italy) ;
Zojer, N. (Center for Oncology, Hematology with Outpatient Department and Palliative Care, Wilhelminenspital, Vienna, Austria) ;
Rajangam, K. (Onyx Pharmaceuticals, Inc.) ;
Chang, Y.L. (Onyx Pharmaceuticals, Inc.) ;
San-Miguel, J.F. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Ludwig, H. (Wilhelminen Cancer Research Institute, Vienna, Austria)
This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). [...]
2017 - 10.1038/leu.2016.176
Leukemia, Vol. 31 (2017) , p. 107-114
|
|
|
5.
|
|
11 p, 858.6 KB |
Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood--a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation
/
Baron, Frédéric (Université de Liège (Bèlgica)) ;
Labopin, Myriam (Hôpital Saint-Antoine (Paris, França)) ;
Ruggeri, Annalisa (Hôpital Saint-Louis (Paris, França)) ;
Mohty, Mohamad (Hôpital Saint-Antoine (Paris, França)) ;
Sanz, Guillermo (Hospital Universitario y Politécnico La Fe (València, País Valencià)) ;
Milpied, Noel (Hôpital Haut Léveque (Pessac, França)) ;
Bacigalupo, Andrea (Ospedale Sant Martino (Genova, Itàlia)) ;
Rambaldi, Alessandro (Azienda Ospedaliera Papa Giovanni XXIII (Bergamo, Itàlia)) ;
Bonifazi, Francesca (Policlinico Sant'Orsola-Malpighi (Bologna, Itàlia)) ;
Bosi, Alberto (Azienda Ospedaliero Universitaria Careggi (Firenze, Itàlia)) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Yakoub-Agha, Ibrahim (Hôpital Claude Huriez (Lille, França)) ;
Ribera Santasusana, J. M. (José María) (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gluckman, Eliane (Hôpital Saint-Louis (Paris, França)) ;
Nagler, Arnon (Sheba Medical Center (Ramat Gran, Israel)) ;
Universitat Autònoma de Barcelona
BACKGROUND: In the setting of allogeneic human leukocyte antigen (HLA)-matched bone marrow transplantation, transplanting male patients with grafts from female donors has been associated with a higher incidence of graft-versus-host disease (GVHD) and of nonrelapse mortality (NRM). [...]
2015 - 10.1186/s13045-015-0207-4
Journal of hematology & oncology, Vol. 8 Núm. 107 (october 2015)
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
